Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.65 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27741346 | 1.00 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBKDR | |
| SCHEMBL5481178 | 0.98 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBKDR | |
| SCHEMBL9668597 | 0.94 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBKDR | |
| SCHEMBL19686245 | 0.87 | PI4KA (0.51) | PI4KAPI4K2BPI4K2API4KBKDR | |
| SCHEMBL7211994 | 0.84 | PI4KA (0.49) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL27761904 | 0.84 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBGPR84 | |
| SCHEMBL6029471 | 0.83 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL5066797 | 0.80 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6683145 | 0.79 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL4551802 | 0.79 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2020-04-02 | — | — | US | disclosed |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| EP-3033338-A2 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023976-A2 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | PI4KA 1654/4885PI4K2B 2005/4885PI4K2A 2260/4885 |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | PI4KA 1654/4885PI4K2B 2005/4885PI4K2A 2260/4885 |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | PI4KA 1654/4885PI4K2B 2005/4885PI4K2A 2260/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | PI4KA 1654/4885PI4K2B 2005/4885PI4K2A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.